Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ND0612 versus Duodopa relative bioavailability study in advanced Parkinson's disease
2017-002780-17Phase 3Completed
- Sponsor
- NeuroDerm Ltd.
- Start
- Feb 2018
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ND0612 and levodopa in Parkinson's disease (PD) (4 arms), sponsored by NeuroDerm Ltd. Primary endpoint: Relative bioavailability of levodopa. Started Feb 2018; status: completed.
02
Drugs
ND0612levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2017-002780-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002780-17.